News ImmuneRegen NewsImmuneRegen BioSciences Holdings Inc Establishes Research Entity in SingaporeBiotech Company to Test for Efficacy in Treating SARS, Avian Flu, Toxic Inhalation Scottsdale, AZ - March 29, 2004 - IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO), owner of biotechnology research and development company ImmuneRegen BioSciences, Inc., today announced it has established a research entity in Singapore and has created IMM BioSciences Asia, Ltd. IR BioSciences Holdings, Inc. will license the use of its proprietary compound Homspera through this new entity for studies on the compound's efficacy in potentially treating adverse effects of cancer, cigarette smoking, influenza, SARS/Avian Flu, HIV among others. The future studies are expected to be held at research labs located at Biopolis, a center for biomedical sciences located in close proximity to the National University of Singapore, University Hospital and the Singapore Science Parks. The campus currently houses many mid-size and large biotech companies, as well as several key government agencies, publicly funded research institutes and R&D labs. "We chose this facility very carefully," explains Michael K. Wilhelm, CEO of ImmuneRegen BioSciences, Inc. "This facility mirrored our needs and corporate direction. The overall design encourages strategic assistance and fosters a collaborative culture among the private and public research community, which is key in any research study. We are currently working on securing the space and should be moving ahead with our studies shortly." About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|